CTSA Visiting Scholar – Therapeutic Advances in Hereditary Hemorrhagic Telangiectasia
VirtualJoin CTSA visiting scholar Hanny Al-Samkari, MD, as he discusses the use of bevacizumab, a humanized monoclonal antibody that targets VEGF, to treat hereditary hemorrhagic telangiectasia (HHT) — a rare disorder that causes anemia and often requires transfusions to treat.